J W Moul

Summary

Affiliation: Center for Prostate Disease Research
Country: USA

Publications

  1. ncbi Screening for prostate cancer in African Americans
    J W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Curr Urol Rep 1:57-64. 2000
  2. ncbi The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Clin North Am 28:459-72. 2001
  3. ncbi Molecular markers in prostate cancer: the role in preoperative staging
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Clin Prostate Cancer 1:42-50. 2002
  4. ncbi Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda 20852, USA
    J Urol 171:1141-7. 2004
  5. ncbi Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003
    Judd W Moul
    Department of Defense Center for Prostate Cancer Research, Rockville, Maryland 20852, USA
    Urology 62:20-8. 2003
  6. ncbi Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urol Oncol 21:447-55. 2003
  7. ncbi Population screening for prostate cancer and emerging concepts for young men
    Judd W Moul
    Walter Reed Army Medical Center Washington, DC, USA
    Clin Prostate Cancer 2:87-97. 2003
  8. ncbi Variables in predicting survival based on treating "PSA-only" relapse
    Judd W Moul
    Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Oncol 21:292-304. 2003
  9. ncbi Early prostate cancer: prevention, treatment modalities, and quality of life issues
    J W Moul
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, 1530 E Jefferson St, Rockville, MD 20852, USA
    Eur Urol 44:283-93. 2003
  10. ncbi Outcome research: prostate cancer databases
    Judd W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Urol Oncol 7:39-42. 2002

Collaborators

Detail Information

Publications94

  1. ncbi Screening for prostate cancer in African Americans
    J W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Curr Urol Rep 1:57-64. 2000
    ....
  2. ncbi The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Clin North Am 28:459-72. 2001
    ..In the long-term, multiple gene expression profiling of biopsy material using gene chips may revolutionize the care of patients with prostate cancer and those who elect radical prostatectomy...
  3. ncbi Molecular markers in prostate cancer: the role in preoperative staging
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Clin Prostate Cancer 1:42-50. 2002
    ..Still, this area holds great promise for improving the accuracy of staging and providing a more accurate prognosis of individual men with clinically localized prostate cancer...
  4. ncbi Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda 20852, USA
    J Urol 171:1141-7. 2004
    ....
  5. ncbi Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003
    Judd W Moul
    Department of Defense Center for Prostate Cancer Research, Rockville, Maryland 20852, USA
    Urology 62:20-8. 2003
    ..Additional studies are needed, however, to define how to optimally use hormone therapy across various patient types...
  6. ncbi Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urol Oncol 21:447-55. 2003
    ..In a broad practice experience represented here, autologous blood donation would appear to be unnecessary for the majority of men and the blood loss advantage traditionally associated with perineal RP is no longer evident...
  7. ncbi Population screening for prostate cancer and emerging concepts for young men
    Judd W Moul
    Walter Reed Army Medical Center Washington, DC, USA
    Clin Prostate Cancer 2:87-97. 2003
    ..In the future, a risk-stratified approach using molecular biomarkers and/or proteomics in young men is anticipated...
  8. ncbi Variables in predicting survival based on treating "PSA-only" relapse
    Judd W Moul
    Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Oncol 21:292-304. 2003
    ..Early work would suggest that timing of recurrence, Gleason grade, and PSA velocity or doubling time during relapse are important prognostic factors. New data on PSA doubling time will be presented...
  9. ncbi Early prostate cancer: prevention, treatment modalities, and quality of life issues
    J W Moul
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, 1530 E Jefferson St, Rockville, MD 20852, USA
    Eur Urol 44:283-93. 2003
    ..The impact of therapeutic modality on QoL has become better characterized, as QoL instruments have been developed, validated and applied...
  10. ncbi Outcome research: prostate cancer databases
    Judd W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Urol Oncol 7:39-42. 2002
  11. ncbi Combination hormonal therapy: a reassessment within advanced prostate cancer
    J W Moul
    Center for Prostate Disease Research, Rockville, Maryland 20852 1532, USA
    Prostate Cancer Prostatic Dis 7:S2-7. 2004
    ..Further data are awaited to optimise the use of combination hormonal therapy in these new settings...
  12. ncbi Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 57:174-7. 2001
    ..Certain chemopreventive agents may affect PSA physiology without affecting the disease process itself creating a meaningless epiphenomenon. Young black men may not generally be receptive to PSA testing or chemopreventive trials...
  13. ncbi Quantitative expression profile of PSGR in prostate cancer
    L L Xu
    Center for Prostate Disease Research CPDR, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, MD 20852, USA
    Prostate Cancer Prostatic Dis 9:56-61. 2006
    ..Strikingly high-percentage CaP cells overexpress PSGR warrants further studies of PSGR expression alterations to define subsets of CaPs...
  14. ncbi Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma
    E L Paquette
    Center for Prostate Disease Research, Rockville, Maryland 20852, USA
    Cancer 92:2673-9. 2001
    ..It appears reasonable to recommend PSA testing in AA men, who have historically experienced poor outcomes from prostate carcinoma...
  15. ncbi Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes
    L L Xu
    Center for Prostate Disease Research (CPDR, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Int J Cancer 92:322-8. 2001
    ..The discovery of new prostate-specific genes and ARGs provides a unique opportunity to determine the role of these genes in prostate cell growth, differentiation and tumorigenesis...
  16. ncbi PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer
    V Srikantan
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Proc Natl Acad Sci U S A 97:12216-21. 2000
    ....
  17. ncbi CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
    M C Bettencourt
    Department of Surgery, Walter Reed Army Medical Center, Armed Forces Institute of Pathology, Washington, DC, USA
    J Urol 160:459-65. 1998
    ....
  18. ncbi The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases
    D M Moreira
    Division of Urologic Surgery, Department of Surgery, and Duke Prostate Center, Duke University School of Medicine, Durham, NC, USA
    Prostate Cancer Prostatic Dis 13:87-93. 2010
    ..This indicates that currently used predictive models have similar performances among CM and AAM. Therefore, nomograms represent a valid and accurate method to predict BCR regardless of race...
  19. ncbi Investigating 3D tumor distribution for optimized diagnosis of prostate cancer
    J Zeng
    Department of Radiology, Georgetown University Medical Center, Washington, DC 20007, USA
    Stud Health Technol Inform 70:392-8. 2000
    ..By calculating cancer appearance inside each of these zones using a large number of prostate samples, we get the overall distributions of prostate cancers based on which an optimal biopsy protocol can be developed...
  20. ncbi Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients
    A S Merseburger
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 58:729-34. 2001
    ..CONCLUSIONS: Creatinine did not provide independent information for predicting pathologic stage or disease recurrence in patients with early prostate cancer...
  21. ncbi External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence
    R A Petroski
    Center for Prostate Disease Research (CPDR, Rockville, Maryland, USA
    Prostate Cancer Prostatic Dis 7:170-7. 2004
    ..0 ng/dl may have microscopic metastatic disease and a decreased chance of cure with SXRT alone. Continence was further impaired after XRT...
  22. ncbi Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center
    S G Koff
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Prostate Cancer Prostatic Dis 5:152-8. 2002
    ..Clinical stage, pretreatment alkaline phosphatase and PSA nadir can be used to predict response for those men presenting with metastatic prostate cancer...
  23. ncbi Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy
    F R Schroeck
    Division of Urology, Department of Surgery, Duke Prostate Center DPC, Duke University Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 11:371-6. 2008
    ..75. Race and prostate weight were independent predictors for BCR after RP. By incorporating these variables, we developed a nomogram, which provides a highly accurate means for estimating risk of BCR after RP...
  24. ncbi p53 regulates the expression of the tumor suppressor gene maspin
    Z Zou
    Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Biol Chem 275:6051-4. 2000
    ....
  25. ncbi Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    J Urol 166:1322-7. 2001
    ....
  26. ncbi p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein
    G L Griewe
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, 6825 Georgia Ave, NW, Washington, District of Columbia, USA
    Prostate Cancer Prostatic Dis 6:281-5. 2003
    ..The goal of this study was to evaluate p53 gene mutations in focal regions of primary prostate cancers positive by p53 immunostaining...
  27. ncbi PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer
    L L Xu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 4799, USA
    Cancer Res 60:6568-72. 2000
    ....
  28. ncbi Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Eur Urol 35:399-407. 1999
    ..More research is needed to assess new biomarkers and, most importantly, to standardize the methodology for sampling and assaying biomarkers in heterogeneous and multifocal prostate cancer...
  29. ncbi Predicting non-organ-confined prostate cancer in men diagnosed after 2000
    A A Caire
    Division of Urology, Department of Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 13:248-51. 2010
    ..Preoperative information on disease stage may aid in treatment decisions and surgical approach...
  30. ncbi A novel human cancer culture model for the study of prostate cancer
    Y Yasunaga
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, MD 20814, USA
    Oncogene 20:8036-41. 2001
    ..This is the first documented case of an established human prostate cancer cell line from a primary tumor of a prostate cancer patient with telomerase...
  31. ncbi A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group
    R S Lance
    Department of Surgery, Urology Service, Madigan Army Medical Center, Tacoma, Washington, DC 98431-1100, USA
    BJU Int 87:61-5. 2001
    ..9%) than in the RRP group (none, P < 0.05). CONCLUSIONS: In similar populations of patients, RPP offers equivalent organ-confined, margin-positive and biochemical recurrence rates to RRP, while causing significantly less blood loss...
  32. ncbi Predictive value of digital rectal examination for prostate cancer detection is modified by obesity
    D I Chu
    Division of Urologic Surgery and Duke Prostate Center, Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 14:346-53. 2011
    ..081). In conclusion, the predictive value of DRE is dependent on obesity and is significantly higher among obese men than normal-weight men...
  33. ncbi Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients
    A Desai
    Center for Prostate Disease Research (CPDR, Rockville, MD 20852, USA
    Prostate Cancer Prostatic Dis 5:212-8. 2002
    ..Close step-sectioning provides better assurance of organ-confined disease, resulting in enhanced prediction of outcome by pathological (TNM) stage...
  34. ncbi Epidemiology and screening for prostate cancer
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Am J Manag Care 3:1200-5; quiz 1208, 1210. 1997
    ..2. Learn the essential elements of prostate specific antigen testing for patients. 3. Understand the cost-effectiveness and medico-legal/informed consent issues surrounding prostate cancer detection and screening...
  35. ncbi Investigating the distribution of prostate cancer using three-dimensional computer simulation
    M B Opell
    Department of Urology, Georgetown University Hospital, Washington, DC, USA
    Prostate Cancer Prostatic Dis 5:204-8. 2002
    ..Through an analysis of the spatial distribution of prostate cancer, we believe that new optimal biopsy strategies and techniques can be developed...
  36. ncbi Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database
    S J Freedland
    Department of Surgery, Duke University School of Medicine, Veterans Affairs Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 12:259-63. 2009
    ..In this study, obese men undergoing radical prostatectomy had higher-grade and larger tumors, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers...
  37. ncbi Managing advanced prostate cancer with Viadur (leuprolide acetate implant)
    J W Moul
    Department of Defense Center for Prostate Disease Research, Uniformed Services University, Rockville, MD, USA
    Urol Nurs 21:385-8, 393-4; quiz 395-6. 2001
    ..Viadur is one aspect of a comprehensive approach to patient management, which also includes regular followup for prostate-specific antigen testing, digital rectal examination, and other tests throughout the 1-year therapy...
  38. ncbi Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors
    A Heidenreich
    Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    J Urol 159:1725-30. 1998
    ..The aim of our study was to examine TGCT and testicular cancer cell lines for deletions and mutations of the p15 and p16 genes...
  39. ncbi A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate
    L L Xu
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20814 4799, USA
    Genomics 66:257-63. 2000
    ..PMEPA1, along with other highly androgen-induced prostate-specific genes, has potential to serve as an androgen signaling read-out biomarker in prostate tissue...
  40. ncbi The development of erectile dysfunction in men treated for prostate cancer
    T Siegel
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, USA
    J Urol 165:430-5. 2001
    ..CONCLUSIONS: Erectile dysfunction develops in greater than 80% of patients treated for prostate cancer. External beam radiation has the same risk for erectile dysfunction as radical prostatectomy...
  41. ncbi Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
    J P Gaddipati
    Urology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001
    Cancer Res 54:2861-4. 1994
    ..The stimulatory effect of these therapeutic agents on the codon 877 mutant AR further suggests that this frequently observed AR mutation may contribute to the treatment refractory disease...
  42. ncbi Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer
    Stephen A Brassell
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Urology 66:1229-33. 2005
    ..We also compared all PSAD derivatives to determine consistency...
  43. ncbi Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Ping Zhou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 23:6992-8. 2005
    ..We evaluated predictors of prostate cancer-specific mortality (PCSM) after prostate-specific antigen (PSA) failure after radical prostatectomy (RP) or radiation therapy (RT)...
  44. ncbi Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years
    Leon Sun
    Division of Urology and Duke Prostate Center, Department of Surgery, Duke University Medical, Center, Durham, NC, USA
    BJU Int 99:753-7. 2007
    ..To identify threshold values of prostate-specific antigen (PSA) levels and PSA velocity (PSAV) to optimize the assessment of the risk of prostate cancer in young men, as prostate cancer is detected increasingly in men aged <50 years...
  45. ncbi Rising prostate-specific antigen after primary prostate cancer therapy
    John F Ward
    Nevada Cancer Institute, Las Vegas, Nevada, USA
    Nat Clin Pract Urol 2:174-82. 2005
    ..Data from animal models provide a rationale for the use of these therapies, but there is a lack of evidence to support prolongation of progression-free survival or cancer-specific survival...
  46. ncbi Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure
    Alexandra J Stewart
    Brigham and Women s Hospital, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6556-60. 2005
    ..2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM)...
  47. ncbi Treating the biochemical recurrence of prostate cancer after definitive primary therapy
    John F Ward
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Clin Prostate Cancer 4:38-44. 2005
    ..The potential opportunities for novel therapeutic agents with low associated morbidity are great...
  48. ncbi Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality
    Jason A Efstathiou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 68:342-7. 2006
    ..A PSA-DT of less than 3 months is a surrogate endpoint for PCSM...
  49. ncbi Prostate-specific antigen screening among young men in the United States
    Charles D Scales
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Cancer 113:1315-23. 2008
    ..Little is known about the use of PSA testing in these men. To understand policy implications of risk stratification, the authors sought to characterize PSA use among young men...
  50. ncbi Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the re
    Michael S Cookson
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Urol 177:540-5. 2007
    ....
  51. ncbi Prostate cancer in the Baby Boomer generation: results from CaPSURE
    Charles D Scales
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 70:1162-7. 2007
    ..We sought to characterize prostate cancer (CaP) presentation among this group, and determine whether treatment patterns differ between Baby Boomers and the preceding generation...
  52. ncbi Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy
    Florian R Schroeck
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    BJU Int 102:28-32. 2008
    ..To compare the prostate-specific antigen (PSA) recurrence (PSAR) rates in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP) or radical retropubic prostatectomy (RRP)...
  53. ncbi Rising PSA in nonmetastatic prostate cancer
    Judd W Moul
    Division of Urologic Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA
    Oncology (Williston Park) 21:1436-45; discussion 1449, 1452, 1454. 2007
    ..In this article, we will explore these prostate cancer disease states with an emphasis on practical, clinically applicable approaches...
  54. ncbi Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens
    Darren E Whittemore
    Department of Pathology, Mike O Callaghan Federal Hospital, Nellis Air Force Base, Nevada, USA
    J Urol 179:516-22; discussion 522. 2008
    ..The Gleason grading system in reporting prostate cancer accounts for the primary and secondary Gleason pattern. The clinical significance of a higher tertiary (third most prevalent) grade is largely unrecognized...
  55. ncbi Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer
    Vladimir Mouraviev
    Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer 110:906-10. 2007
    ....
  56. ncbi Erectile function outcome reporting after clinically localized prostate cancer treatment
    Arthur L Burnett
    The Johns Hopkins Hospital, 600 North Wolfe St, Marburg 407, Baltimore, Maryland 21287 2411, USA
    J Urol 178:597-601. 2007
    ....
  57. ncbi Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 110:56-61. 2007
    ..Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors...
  58. ncbi Guideline for the management of clinically localized prostate cancer: 2007 update
    Ian Thompson
    American Urological Association Education and Research, Inc
    J Urol 177:2106-31. 2007
  59. ncbi Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy
    Thomas J Polascik
    Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Prostate 68:1380-6. 2008
    ..We evaluated trends in pathologic staging among patients with localized PCa undergoing radical prostatectomy (RP), defining the frequency of unilateral cancers during 1988-1995, 1996-2000 and 2001-2006...
  60. ncbi Percent tumor involvement and risk of biochemical progression after radical prostatectomy
    Edward N Rampersaud
    Division of Urologic Surgery, Duke Prostate Center, Durham, North Carolina, USA
    J Urol 180:571-6; discussion 576. 2008
    ..We hypothesized percent tumor involvement may be a good correlate of outcome in all stages of prostate cancer...
  61. ncbi Prostate specific antigen recurrence after definitive therapy
    Stephen J Freedland
    Division of Surgery, Durham Veterans Affairs Medical Center, Durham, NC, USA
    J Urol 177:1985-91. 2007
    ..However, to do so the risks and benefits of the various options must be known. Therefore, we provide a comprehensive overview of the natural history and treatment options for men with prostate specific antigen-only recurrence...
  62. ncbi Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience
    Vladimir Mouraviev
    Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 69:311-4. 2007
    ....
  63. ncbi Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases
    Stephen J Freedland
    Urology Section, Department of Surgery, Veterans Affairs Medical Center, Duke University Medical Center, Durham, NC 27710, USA
    BJU Int 102:969-74. 2008
    ....
  64. ncbi Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line
    Yongpeng Gu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Anticancer Res 25:1-8. 2005
    ..NKX 3.1 and epithelial cell specific cytokeratin 8, androgen receptor (AR), prostate stem cell antigen and p16, but not PSA. AR protein was detected by Western blot analysis...
  65. ncbi Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer
    John F Ward
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Opin Urol 15:187-95. 2005
    ..Multimodal therapy improves cancer-specific outcomes especially in men with high-risk disease. The potential opportunities for novel therapeutic agents with low associated morbidity are great...
  66. ncbi Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer
    John F Ward
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Opin Urol 15:181-6. 2005
    ..The potential therefore exists for prostate-specific antigen doubling time to be accepted as a trial endpoint, which might accelerate drug approval by the United States Food and Drug Administration...
  67. ncbi Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms
    Kevin J Gancarczyk
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 61:589-95. 2003
    ..On the basis of these findings, CPDR probability nomograms were developed to predict pathologic outcome at the time of RP...
  68. ncbi Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Resea
    Peter A S Johnstone
    Investigation Department, Naval Medical Center, San Diego, CA 92134, USA
    Int J Radiat Oncol Biol Phys 55:964-9. 2003
    ..The records of the Department of Defense Center for Prostate Disease Research were queried for the biochemical disease-free results of patients after definitive RT and analyzed by age...
  69. ncbi PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium
    Bob Djavan
    Department of Urology, University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Eur Urol 43:12-27. 2003
    ..At last, the use of artificial neural networks will certainly enhance the selection of patients submitted to radical treatments as well as the selection of relapsing patients to allow a more appropriate adjuvant therapy...
  70. ncbi The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL
    Bill P Vanasupa
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, Maryland 20852, USA
    Urol Oncol 7:167-72. 2002
    ..While surgery alone is unlikely to cure prostate cancer in these patients, surgery in conjunction with hormonal or radiation therapy may prolong survival with acceptable effects on urinary continence and potency...
  71. ncbi Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues
    Axel S Merseburger
    Department of Genitourinary Pathology, Armed Forces Institute of Pathology (AFIP, Washington, DC 20306-6000, USA
    Oncol Rep 10:223-8. 2003
    ..The TMA technique is probably more informative and reliable in evaluating the prognostic value of homogeneously expressed biomarkers...
  72. ncbi Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing
    Edmond L Paquette
    Center for Prostate Disease Research, Rockville, Maryland 20852, USA
    Urology 60:756-9. 2002
    ..This portends well for the use of PSA screening to improve outcomes for prostate cancer. However, randomized trials are needed to confirm the improvements in survival and mortality...
  73. ncbi Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Researc
    Peter A S Johnstone
    Naval Medical Ctr, San Diego, Calif 92134 1014, USA
    Radiology 225:420-6. 2002
    ..To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy...
  74. ncbi Screening for prostate cancer in high risk populations
    William J Catalona
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
    J Urol 168:1980-3; discussion 1983-4. 2002
    ..On initial screening of high risk men in their fourth decade only 8% have positive screening tests; however, approximately 55% of these men have tumors, most of which are medically important with favorable prognostic features...
  75. ncbi Prostate-specific antigen as a marker of disease activity in prostate cancer
    Alan W Partin
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Oncology (Williston Park) 16:1218-24; discussion 1224, 1227-8 passim. 2002
    ..Part 2 of this two-part article, which began in the August issue, discusses the role of PSA in hormonal and drug therapies and in primary and secondary chemoprevention...
  76. ncbi Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database
    Judd W Moul
    Urology Service, Dept of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Surgery 132:213-9. 2002
    ..The operation is now performed more rapidly with less blood loss, and the surgical pathology outcome end points and early disease-free survival are improved. These results portend well for improved long-term outcomes of surgical therapy...
  77. ncbi Prostate-specific antigen as a marker of disease activity in prostate cancer
    Alan W Partin
    Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    Oncology (Williston Park) 16:1024-38, 1042; discussion 1042, 1047-8, 1051. 2002
    ..Part 1 of this two-part article, which concludes in the September issue, focuses on the physiology of PSA, its measurement and use in clinical practice, and its predictive value following radical prostatectomy and radiation therapy...
  78. ncbi Cadmium-induced neoplastic transformation of human prostate epithelial cells
    Keiichiro Nakamura
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Int J Oncol 20:543-7. 2002
    ..1 and cytokeratin 8 (CK8). These findings provide evidence of malignant transformation of human prostate epithelial cells exposed to this environmentally important chemical...
  79. ncbi Predictors of extracapsular extension and positive margins in African American and white men
    Edmond L Paquette
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Urol Oncol 21:33-8. 2003
    ..Close follow-up of these patients is warranted to determine if the improved pathologic stage of those patients treated more recently translates into improved disease-specific mortality...
  80. ncbi Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
    Jason C Massengill
    Department of Surgery, Center for Prostatic Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    J Urol 169:1670-5. 2003
    ..As testosterone decreases patients have an increased likelihood of non-organ confined disease. Low testosterone was not predictive of biochemical recurrence, although trends observed dictate study in larger cohorts with mature followup...
  81. ncbi A novel neoplastic primary tumor-derived human prostate epithelial cell line
    Daejin Ko
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Int J Oncol 22:1311-7. 2003
    ..This is the first documented case of a malignant AR and PSA positive established human prostate cancer cell line from a primary tumor of a prostate cancer patient...
  82. ncbi Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
    Gyorgy Petrovics
    Center for Prostate Disease Research CPDR, Department of Surgery and US Military Cancer Institute, Uniformed Services University, Rockville, MD 20852, USA
    Oncogene 24:3847-52. 2005
    ....
  83. ncbi Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy
    Judd W Moul
    Division of Urologic Surgery and Duke Prostate Cancer, Duke University, Durham, NC 27710, USA
    BJU Int 95:285-90. 2005
  84. ncbi A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes
    Yongpeng Gu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Service University of Health Sciences, Bethesda, MD 20814, USA
    Int J Oncol 25:1057-64. 2004
    ..This is the first documented case of an AR and PSA expressing telomerase established human prostate cancer cell line with neoplastic phenotypes from a primary tumor of a prostate cancer patient...
  85. ncbi p63 expression profile in normal and malignant prostate epithelial cells
    Leland D Davis
    Center for Prostate Disease Research (CPDR, Department of Surgery, Uniformed Services University of the Health Sciences, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Anticancer Res 22:3819-25. 2002
    ..The basal cell association underscores its critical functions in the biology of basal cells...
  86. ncbi Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 96:509-15. 2004
    ....
  87. ncbi Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients
    Gyorgy Petrovics
    Department of Surgery, Center for Prostate Disease Research, US Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Oncogene 23:605-11. 2004
    ....
  88. ncbi Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy
    Christopher L Amling
    Department of Urology, Naval Medical Center, 34800 Bob Wilson Drive, San Diego, CA 92134 5000, USA
    J Clin Oncol 22:439-45. 2004
    ....
  89. ncbi Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..The efficacy appears to be greater in patients who can achieve a PSA nadir of 0.1 ng/mL or less after the start of treatment...
  90. ncbi Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era
    Corey A Carter
    Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    J Clin Oncol 21:4001-8. 2003
    ..PSA DTs often predict the use of secondary treatment. The number of comorbidities a patient has influences the type of secondary therapy chosen. The WW strategy may better be termed temporarily deferred therapy...
  91. ncbi Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 95:1376-83. 2003
    ..Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer-specific mortality by analyzing two multi-institutional databases...
  92. ncbi Biochemical recurrence of prostate cancer
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Services, Bethesda, Maryland, USA
    Curr Probl Cancer 27:243-72. 2003
  93. ncbi Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients
    Chun-Ling Gao
    Center for Prostate Disease Research, Department of Surgery, Uniformed Service University of the Health Science, Bethesda, Maryland 20814-4799, USA
    Clin Cancer Res 9:2545-50. 2003
    ..Strong concordance between the biopsy results and ERT-PCR/PSA assay (sensitivity 81.8%; specificity 87.1%) suggests a potentially new diagnostic application of this type of assay in CaP diagnosis...
  94. ncbi Prostate biopsy quantitative histology as a staging and prognostic factor
    Judd W Moul
    J Urol 167:526-7. 2002